Study of CRMA-1001 for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial tests a new drug called CRMA-1001 in people with chronic hepatitis B who are already on antiviral therapy. The goal is to see if it can help control the virus better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old
- You weigh between 45 and 150 kg (about 99 to 330 pounds)
- You have been diagnosed with chronic hepatitis B
- You are currently taking oral antiviral medication for hepatitis B
- Your liver enzyme levels (ALT and AST) are no more than 1.5 times the upper limit of normal
- Your total bilirubin level is within normal range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Hear when a new Chronic Hepaititis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.